Fundraising Fox

F2G

10 known investors

f2g.com ↗

F2G is a biotechnology company developing novel antifungal therapies to treat rare, life-threatening fungal infections in defined patient populations. Its work centers on new drug science aimed at expanding treatment options against fungal pathogens.

BiotechHealthtech

Investors · 10

Advent Life SciencesLondon
Aisling CapitalNew York
AMR Action FundBoston
Astellas Venture Management LLCSouth San Francisco · $200K – $5M
Brace PharmaAtlanta
Sofinnova PartnersParis · $540K – $27M
Sunstone CapitalFrederiksberg
ForbionreportedNaarden
Merifin CapitalreportedBrussels · $216K – $3.2M
Novartis Venture FundreportedBasel · $5M – $25M

In the news

F2G CEO outlines biotech’s FDA resubmission plans, funding and expansionendpoints.news · Jan 2026F2G raises $100M to bring antifungal drug back to FDA | BioPharma Divebiopharmadive.com · Sep 2024F2G raises $100M to fund 2nd attempt to get new antifungal class to marketfiercebiotech.com · Sep 2024F2G Raises $70M in Financingfinsmes.com · Aug 2022UPDATED: Novartis, Novo-backed antifungal biotech F2G raises $60M | Fierce Biotechfiercebiotech.com · Jun 2016F2G raises $60m in financing to develop invasive fungal infections therapies - Pharmaceutical Technologypharmaceutical-technology.com · Jun 2016

Frequently asked questions

What does F2G do?
F2G is a biotechnology company developing novel antifungal therapies to treat rare, life-threatening fungal infections in defined patient populations. Its work centers on new drug science aimed at expanding treatment options against fungal pathogens.
Who are F2G's investors?
F2G's investors include Advent Life Sciences, Aisling Capital, AMR Action Fund, Astellas Venture Management LLC, Brace Pharma, Sofinnova Partners, Sunstone Capital, Forbion and 2 more.